ANT-GROUP
3.11.2022 04:21:38 CET | Business Wire | Press release
Ant Group today officially launched its Alipay+ D-store™ at the Singapore FinTech Festival 2022. Alipay+ D-store™ is a business digitalization solution designed to support the service industry, especially brick-and-mortar businesses to digitalize their operations to boost efficiency and productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221102006207/en/
(Photo: Business Wire)
An integrated one-stop solution which businesses can use to build digital stores across multiple digital platforms in a fast, scalable and cost-efficient way, Alipay+ D-store™ provides a suite of toolkits to digitalize merchants' payments, operations, services and marketing, unlocking new revenue opportunities and delivering better services to consumers.
Businesses could have digital stores on digital platforms in the form of mini programmes. Digital stores could also be developed as H5 pages and easily embedded in social media and online to reach consumers. Digital platforms currently partnering with Alipay+ D-store™ include Chope, Alipay, Touch 'n Go eWallet, AlipayHK, etc.
“We welcome more digital platforms to collaborate to accelerate the digitalization of the global service industry together,” Dr. Cherry Huang, Global Head of Alipay+ D-store™ said.
“Leveraging digital solutions is critical for the service industries to boost operational efficiency and adapt to the fast-changing market conditions. The Alipay+ D-store™ solution is developed with the goal to make it easier for brick-and-mortar businesses to go digital at scale, so that businesses can better serve and engage digital-savvy consumers by providing a seamless omni-channel experience,” she added.
Having identified the F&B industry a priority sector, Alipay+ D-store™ solution has been adopted by brands including fast food chain Burger King, Koufu, one of Singapore’s most established and largest operators and managers of food courts and coffee shops, and more than 2,000 local restaurants, cafes and eateries in Singapore, Malaysia, Hong Kong SAR, China and other markets.
At the Festival, Alipay+ D-store™ also unveiled its newest customer, Huggs Coffee, one of Singapore’s largest homegrown cafe chain brands specializing in coffee with over 20 outlets. Huggs will work with Alipay+ D-store™ to digitalize its outlets and operations efficacy, allowing customers to access seamless services through its digital store on Chope and other platforms in future.
Speaking in regard to the partnership, Lee Haoming, Managing Director of Huggs Coffee said: “Huggs is not only a business of F&B, to us, a good cup of coffee is a tool to create social connections. That is why creating a unique and elevated experience beyond the coffee itself is important to Huggs, and we believe digitalization plays an important role in enhancing the experience.”
“We are very excited to partner with Alipay+ D-store™ to transform the Huggs experience! It creates a more efficient operation flow to brew more smiles while reducing time to queue and pay, henceforth allowing our valued customers to spend more quality time on building connections with each other when visiting Huggs.”
To learn more about Alipay+ D-store™ at the Singapore FinTech Festival 2022, visit the Ant Group booth #2E01, or attend the product showcase “It’s A PLUS: How Alipay+ & Partners Build Digital Resilience For Businesses” scheduled at 11:20 a.m., 3 November in Hall 3.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, it strives to provide all consumers and small and micro businesses equal access to digital, financial, and other daily life services that are convenient, sustainable, and inclusive.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102006207/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
